Skip to main content
Erschienen in: Breast Cancer Research and Treatment 2/2015

01.09.2015 | Epidemiology

Complex fibroadenoma and breast cancer risk: a Mayo Clinic Benign Breast Disease Cohort Study

verfasst von: Aziza Nassar, Daniel W. Visscher, Amy C. Degnim, Ryan D. Frank, Robert A. Vierkant, Marlene Frost, Derek C. Radisky, Celine M. Vachon, Ruth A. Kraft, Lynn C. Hartmann, Karthik Ghosh

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

The purpose of this study is to examine the breast cancer risk overall among women with simple fibroadenoma or complex fibroadenoma and to examine the association of complex fibroadenoma with breast cancer through stratification of other breast cancer risks. The study included women aged 18–85 years from the Mayo Clinic Benign Breast Disease Cohort who underwent excisional breast biopsy from 1967 through 1991. Within this cohort, women who had fibroadenoma were compared to women who did not have fibroadenoma. Breast cancer risk (observed versus expected) across fibroadenoma levels was assessed through standardized incidence ratios (SIRs) by using age- and calendar-stratified incidence rates from the Iowa Surveillance, Epidemiology, and End Results registry. Analyses were performed overall, within subgroups of involution status, with other demographic characteristics (age, year of biopsy, indication for biopsy, and family history), and with histologic characteristics, including overall impression [nonproliferative disease, proliferative disease without atypia (PDWA), or atypical hyperplasia]. Fibroadenoma was identified in 2136 women [noncomplex, 1835 (85.9 %); complex, 301 (14.1 %)]. SIR for noncomplex fibroadenoma was 1.49 (95 % CI 1.26–1.74); for complex fibroadenoma, it was 2.27 (95 % CI 1.63–3.10) (test for heterogeneity in SIR, P = .02). However, women with complex fibroadenoma were more likely to have other, concomitant high-risk histologic characteristics (e.g., incomplete involution and PDWA). In analyses stratified by involution status and PDWA, complex fibroadenoma was not an independent risk marker for breast cancer. Complex fibroadenoma does not confer increased breast cancer risk beyond other established histologic characteristics.
Literatur
1.
Zurück zum Zitat Kuijper A, Mommers EC, van der Wall E, van Diest PJ (2001) Histopathology of fibroadenoma of the breast. Am J Clin Pathol 115(5):736–742CrossRefPubMed Kuijper A, Mommers EC, van der Wall E, van Diest PJ (2001) Histopathology of fibroadenoma of the breast. Am J Clin Pathol 115(5):736–742CrossRefPubMed
2.
Zurück zum Zitat Dupont WD, Page DL, Parl FF et al (1994) Long-term risk of breast cancer in women with fibroadenoma. N Engl J Med 331(1):10–15CrossRefPubMed Dupont WD, Page DL, Parl FF et al (1994) Long-term risk of breast cancer in women with fibroadenoma. N Engl J Med 331(1):10–15CrossRefPubMed
3.
Zurück zum Zitat McDivitt RW, Stevens JA, Lee NC, Wingo PA, Rubin GL, Gersell D, The Cancer and Steroid Hormone Study Group (1992) Histologic types of benign breast disease and the risk for breast cancer. Cancer 69(6):1408–1414CrossRefPubMed McDivitt RW, Stevens JA, Lee NC, Wingo PA, Rubin GL, Gersell D, The Cancer and Steroid Hormone Study Group (1992) Histologic types of benign breast disease and the risk for breast cancer. Cancer 69(6):1408–1414CrossRefPubMed
4.
Zurück zum Zitat Kabat GC, Jones JG, Olson N et al (2010) A multi-center prospective cohort study of benign breast disease and risk of subsequent breast cancer. Cancer Causes Control 21(6):821–828PubMedCentralCrossRefPubMed Kabat GC, Jones JG, Olson N et al (2010) A multi-center prospective cohort study of benign breast disease and risk of subsequent breast cancer. Cancer Causes Control 21(6):821–828PubMedCentralCrossRefPubMed
5.
Zurück zum Zitat El-Wakeel H, Umpleby HC (2003) Systematic review of fibroadenoma as a risk factor for breast cancer. Breast 12(5):302–307CrossRefPubMed El-Wakeel H, Umpleby HC (2003) Systematic review of fibroadenoma as a risk factor for breast cancer. Breast 12(5):302–307CrossRefPubMed
6.
Zurück zum Zitat Hartmann LC, Sellers TA, Frost MH et al (2005) Benign breast disease and the risk of breast cancer. New Engl J Med 353(3):229–237CrossRefPubMed Hartmann LC, Sellers TA, Frost MH et al (2005) Benign breast disease and the risk of breast cancer. New Engl J Med 353(3):229–237CrossRefPubMed
7.
Zurück zum Zitat Milanese TR, Hartmann LC, Sellers TA et al (2006) Age-related lobular involution and risk of breast cancer. J Natl Cancer Inst 98(22):1600–1607CrossRefPubMed Milanese TR, Hartmann LC, Sellers TA et al (2006) Age-related lobular involution and risk of breast cancer. J Natl Cancer Inst 98(22):1600–1607CrossRefPubMed
8.
Zurück zum Zitat Page DL, Anderson TJ (1987) Diagnostic histopathology of the breast. Churchill Livingstone, Edinburgh Page DL, Anderson TJ (1987) Diagnostic histopathology of the breast. Churchill Livingstone, Edinburgh
9.
Zurück zum Zitat Fibroadenoma AJG (1979) Problems in breast pathology. In: Bennington JL (ed) Major problems in pathology, vol 11. Saunders, Philadelphia Fibroadenoma AJG (1979) Problems in breast pathology. In: Bennington JL (ed) Major problems in pathology, vol 11. Saunders, Philadelphia
10.
11.
Zurück zum Zitat Ozzello L, Gump FE (1985) The management of patients with carcinomas in fibroadenomatous tumors of the breast. Surg Gynecol Obstet 160(2):99–104PubMed Ozzello L, Gump FE (1985) The management of patients with carcinomas in fibroadenomatous tumors of the breast. Surg Gynecol Obstet 160(2):99–104PubMed
12.
Zurück zum Zitat Deschenes L, Jacob S, Fabia J, Christen A (1985) Beware of breast fibroadenomas in middle-aged women. Can J Surg 28(4):372–374PubMed Deschenes L, Jacob S, Fabia J, Christen A (1985) Beware of breast fibroadenomas in middle-aged women. Can J Surg 28(4):372–374PubMed
13.
Zurück zum Zitat Buzanowski-Konakry K, Harrison EG Jr, Payne WS (1975) Lobular carcinoma arising in fibroadenoma of the breast. Cancer 35(2):450–456CrossRefPubMed Buzanowski-Konakry K, Harrison EG Jr, Payne WS (1975) Lobular carcinoma arising in fibroadenoma of the breast. Cancer 35(2):450–456CrossRefPubMed
14.
Zurück zum Zitat Cant PJ, Madden MV, Coleman MG, Dent DM (1995) Non-operative management of breast masses diagnosed as fibroadenoma. Br J Surg 82(6):792–794CrossRefPubMed Cant PJ, Madden MV, Coleman MG, Dent DM (1995) Non-operative management of breast masses diagnosed as fibroadenoma. Br J Surg 82(6):792–794CrossRefPubMed
15.
Zurück zum Zitat Ciatto S, Bonardi R, Zappa M, Giorgi D (1997) Risk of breast cancer subsequent to histological or clinical diagnosis of fibroadenoma: retrospective longitudinal study of 3938 cases. Ann Oncol 8(3):297–300CrossRefPubMed Ciatto S, Bonardi R, Zappa M, Giorgi D (1997) Risk of breast cancer subsequent to histological or clinical diagnosis of fibroadenoma: retrospective longitudinal study of 3938 cases. Ann Oncol 8(3):297–300CrossRefPubMed
Metadaten
Titel
Complex fibroadenoma and breast cancer risk: a Mayo Clinic Benign Breast Disease Cohort Study
verfasst von
Aziza Nassar
Daniel W. Visscher
Amy C. Degnim
Ryan D. Frank
Robert A. Vierkant
Marlene Frost
Derek C. Radisky
Celine M. Vachon
Ruth A. Kraft
Lynn C. Hartmann
Karthik Ghosh
Publikationsdatum
01.09.2015
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 2/2015
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-015-3535-8

Weitere Artikel der Ausgabe 2/2015

Breast Cancer Research and Treatment 2/2015 Zur Ausgabe

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.